Abstract
Ciclesonide, a new inhaled corticosteroid, is administered as a parent compound and converted in the airway mucosa into the active metabolite, desisobutyryl-(des-)ciclesonide. A study was designed to evaluate the ability of ciclesonide to modulate pro-inflammatory functions of human bronchial epithelial cell (HBEC) primary cultures being converted into des-ciclesonide. HBECs were stimulated with interleukin (IL)-4 and tumour necrosis factor (TNF)-α (20 ng/mL) in the presence of ciclesonide and intercellular adhesion molecule (ICAM)-1 expression, granulocyte-macrophage colony stimulating factor (GM-CSF) and IL-8 release evaluated respectively by FACS and ELISA. Ciclesonide (3 μM) significantly inhibited ICAM-1 expression by stimulated HBECs, already after 3 h and still after 48 h culture (p
Original language | English |
---|---|
Pages (from-to) | 210-217 |
Number of pages | 8 |
Journal | Pulmonary Pharmacology and Therapeutics |
Volume | 19 |
Issue number | 3 |
DOIs | |
Publication status | Published - Jun 2006 |
Keywords
- Adhesion molecule expression
- Airway epithelial cells
- Asthma
- Chemokines
- Ciclesonide
- Cytokines
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
- Pharmacology